论文信息 - Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial - 字舞流文

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

R. Schooley | R. Gross | J. Mellors | A. Collier | B. Grinsztejn | C. Godfrey | P. Mugyenyi | L. Mohapi | V. Mave | N. Kumarasamy | E. Hogg | C. Wallis | A. Avihingsanon | B. Santos | S. W. Cardoso | C. Kanyama | M. Chagomerana | R. Secours | Wadzanai P Samaneka | R. Mngqibisa | P. Sugandhavesa | Aggrey Bukuru | Mumbi Makanga | M. Van Schalkwyk | Javier Valencia | E. Montalbán | S. N. Fontain | M. Hughes | R. Salata | Caitlyn McCarthy | Sharlaa Badal‐aesen | Beatrice Wangari Ndege | Cornelius Munyanga | J. Valencia